Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Poor Survival Outcomes Among Patients with Burkitt Lymphoma Are Associated with Socioeconomic Disparities

Oluwasegun Akinyemi, Faith O Abodunrin, Oluwatayo Adeoye, Akinwale Akingbule, Olanrewaju Oni, Bolarinwa Akinwumi, Ademola Ojo, Oluwaseun B Ogunbona, Peter Silberstein

Blood (2022) 140 (Supplement 1): 8103–8104.

https://doi.org/10.1182/blood-2022-168916

Published: 2022

Journal Articles

Utilization of Palliative Care in Diffuse Large B Cell Lymphoma Patients Is Linked to Insurance Type and Household Income

Faith O Abodunrin, Oluwatayo Adeoye, James O. Armitage, Peter Silberstein, Oluwasegun Akinyemi, Connor Tupper

Blood (2022) 140 (Supplement 1): 10902–10903.

https://doi.org/10.1182/blood-2022-168019

Published: 2022

Journal Articles

Demographics of PTLD Patients Who Died during 2010-2017 Period: A NCDB Based Study

Sai Giridhar Gundepalli, Hussain I Rangoonwala, Peter Silberstein

Blood (2021) 138 (Supplement 1): 4998.

https://doi.org/10.1182/blood-2021-154387

Published: 2021

Journal Articles

Role of Daratumumab in Relapsed and Refractory Multiple Myeloma Patients: Meta-Analysis and Literature Review

Faith O Abodunrin, Abubakar Tauseef, Peter Silberstein

Blood (2021) 138 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2021-151210

Published: 2021

Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD

Blood (2006) 108 (11): 1306.

https://doi.org/10.1182/blood.V108.11.1306.1306

Published: 2006

Journal Articles

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Ralph Vincent Boccia, Delong Liu, Peter Silberstein, Simon Tchekmedyian, Dianne Tomita, Greg Rossi, Greg Otterson

Blood (2004) 104 (11): 5310.

https://doi.org/10.1182/blood.V104.11.5310.5310

Published: 2004

NARROW

Poor Survival Outcomes Among Patients with Burkitt Lymphoma Are Associated with Socioeconomic Disparities

Utilization of Palliative Care in Diffuse Large B Cell Lymphoma Patients Is Linked to Insurance Type and Household Income

Demographics of PTLD Patients Who Died during 2010-2017 Period: A NCDB Based Study

Role of Daratumumab in Relapsed and Refractory Multiple Myeloma Patients: Meta-Analysis and Literature Review

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Email alerts

ASH Publications

American Society of Hematology

Poor Survival Outcomes Among Patients with Burkitt Lymphoma Are Associated with Socioeconomic Disparities

Utilization of Palliative Care in Diffuse Large B Cell Lymphoma Patients Is Linked to Insurance Type and Household Income

Demographics of PTLD Patients Who Died during 2010-2017 Period: A NCDB Based Study

Role of Daratumumab in Relapsed and Refractory Multiple Myeloma Patients: Meta-Analysis and Literature Review

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only